A Phase 1/2 interventional study of AOC 1001 and Placebo in DM1, Myotonic Dystrophy 1 and Myotonic Dystrophy, sponsored by Avidity Biosciences, Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Avidity Biosciences, Inc. (part of Novartis) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Myotonic Dystrophy with a site in United States — 23 open to participants now, 27 under way, 4 of them phase 3. Myotonic Dystrophy · United States.
Among the 43 studies in Myotonic Dystrophy with a site in United States, this one is the 14th largest by enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2021, is one of 7 in phase 1/2, and was the 20th registered.
126 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.
Browse Myotonic Dystrophy studies →23 of the 43 studies in Myotonic Dystrophy with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 14+ · Healthy volunteers
Virginia Commonwealth University · Sites in United States
Ages 18–70
Dyne Therapeutics · Sites in United States
Ages 4–18 · Men only
Dyne Therapeutics · Sites in United States, Australia, Belgium and 9 more countries
Ages 16+
Sanofi · Sites in United States, Argentina, Australia and 3 more countries
Ages 10–55
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 14 · Phase 3 6
First in 2000; this study’s year is marked. 4 started in 2021.
This study's enrollment of 39 is close to the median of 40 across 67 interventional studies indexed under Myotonic Dystrophy.
Median enrollment 46 across the 22 interventional studies, 125 across the 21 observational. Of the 15 that completed or were terminated, 7 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 43 have an industry lead sponsor. The 10 most frequent:
This study is registered under Avidity Biosciences, Inc., one of the names counted as Novartis. Under that name alone:
Avidity Biosciences, Inc. is the lead sponsor of 11 studies on the registry; 4 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Novartis has 5 studies filed under Myotonic Dystrophy — fewer than ten, so there is no comparison to draw.
9 of the studies in Myotonic Dystrophy with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05004129Phase 3AMO Pharma LimitedSafety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy | 2026-12-31 |
| NCT05020002Massachusetts General HospitalExtracellular RNA Biomarkers of Myotonic Dystrophy | 2026-12 |
| NCT05224778Virginia Commonwealth UniversityDMCRN-02-001: Assessing Pediatric Endpoints in DM1 | 2026-12 |
| NCT03981575Virginia Commonwealth UniversityEstab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) | 2026-12-01 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
Add all 9 to your calendar (.ics) → With an account.
Among the 43 studies in Myotonic Dystrophy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
AOC 1001-CS1 is a randomized, double-blind, placebo-controlled, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple-doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) patients (MARINA).
Part A is a single dose design with 1 cohort (dose level). In Part A, the patient duration is 6 months as the treatment period is 1 day followed by a 6 month follow-up period.
Part B is a multiple-ascending dose design with 2 cohorts (dose levels). In Part B, the patient duration is 6 months as the treatment period is 3 months followed by a 3 month follow-up period.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AOC 1001 will be administered once.
Drug: AOC 1001
Saline will be administered once.
Drug: Placebo
AOC 1001 will be administered three times.
Drug: AOC 1001
Saline will be administered three times.
Drug: Placebo
AOC 1001 will be administered by intravenous (IV) infusion.
Placebo will be administered by intravenous (IV) infusion.
Frequency of Treatment Emergent Adverse Events (TEAEs)
Cumulative number of participants with treatment emergent adverse events at the end of study.
Time frame: Through study completion, up to Day 183
Plasma PK Parameters
Maximum concentration in Plasma (Cmax)
Time frame: Day 1
Plasma Pharmacokinetic (PK) Parameters
Time to maximum plasma concentration (Tmax)
Time frame: Day 1
Plasma Pharmacokinetic (PK) Parameters
Terminal Half-life (t1/2)
Time frame: Day 1
Plasma Pharmacokinetic (PK) Parameters
Area Under the Concentration-time Curve (AUC) obtained until the last observed timepoint
Time frame: Day 1
Urine Pharmacokinetic (PK) Parameters
fraction excreted (fe) in urine in first 24 hours
Time frame: Day 1
Change From Baseline in DMPK mRNA Knockdown
percent change from baseline in DMPK mRNA level
Time frame: Day 43 (participants treated with 1 mg/kg) and Day 92 (participants treated with 2 mg/kg and 4 mg/kg)
Absolute Change From Baseline in 4 Gene Spliceopathy
Change from baseline in 4 gene panel mean scaled percent spliced in value. The 4 gene panel includes the following genes: CLCN1, CACNA1S, ATP2A1, and BIN1
Time frame: Day 43 (participants treated with 1 mg/kg) and Day 92 (participants treated with 2 mg/kg and 4 mg/kg)
AOC 1001 Concentration Levels in Plasma, Urine, and Muscle Tissue
AOC 1001 concentration measures in plasma, urine, and muscle tissue. Assessments below lower limit of quantification are set to zero.
Time frame: Up to Day 43
| Milestone | Part A Single Dose: 1 mg/kg AOC 1001 | Part A Single Dose: Placebo | Part B Multiple Dose: 2 mg/kg AOC 1001 | Part B Multiple Dose: 4 mg/kg AOC 1001 | Part B Multiple Dose: Pooled Placebo |
|---|---|---|---|---|---|
| Started | 6 | 2 | 9 | 14 | 8 |
| Completed | 6 | 2 | 9 | 12 | 8 |
| Not completed | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Participant was randomized but not dosed | 0 | 0 | 0 | 1 | 0 |
Cumulative number of participants with treatment emergent adverse events at the end of study.
| Participants | Part A Single Dose: 1 mg/kg AOC 1001 | Part A Single Dose: Placebo | Part B Multiple Dose: 2 mg/kg AOC 1001 | Part B Multiple Dose: 4 mg/kg AOC 1001 | Part B Multiple Dose: Pooled Placebo |
|---|---|---|---|---|---|
| Frequency of Treatment Emergent Adverse Events (TEAEs) | 6 | 1 | 9 | 13 | 7 |
Maximum concentration in Plasma (Cmax)
| ng/mL | Part A Single Dose: 1 mg/kg AOC 1001 | Part B Multiple Dose: 2 mg/kg AOC 1001 | Part B Multiple Dose: 4 mg/kg AOC 1001 |
|---|---|---|---|
| Plasma PK Parameters | 23600 ± 3610 | 50400 ± 9380 | 101000 ± 19200 |
Time to maximum plasma concentration (Tmax)
| hours | Part A Single Dose: 1 mg/kg AOC 1001 | Part B Multiple Dose: 2 mg/kg AOC 1001 | Part B Multiple Dose: 4 mg/kg AOC 1001 |
|---|---|---|---|
| Plasma Pharmacokinetic (PK) Parameters | 0.542 (0.47 to 0.60) | 1.707 (0.72 to 4.77) | 2.204 (1.07 to 7.73) |
Terminal Half-life (t1/2)
| hours | Part A Single Dose: 1 mg/kg AOC 1001 | Part B Multiple Dose: 2 mg/kg AOC 1001 | Part B Multiple Dose: 4 mg/kg AOC 1001 |
|---|---|---|---|
| Plasma Pharmacokinetic (PK) Parameters | 28.42 ± 2.82 | 40.61 ± 9.69 | 49.60 ± 6.08 |
Area Under the Concentration-time Curve (AUC) obtained until the last observed timepoint
| h*ng/mL | Part A Single Dose: 1 mg/kg AOC 1001 | Part B Multiple Dose: 2 mg/kg AOC 1001 | Part B Multiple Dose: 4 mg/kg AOC 1001 |
|---|---|---|---|
| Plasma Pharmacokinetic (PK) Parameters | 850000 ± 137000 | 2470000 ± 629000 | 5490000 ± 1570000 |
fraction excreted (fe) in urine in first 24 hours
| percent of total siRNA component | Part A Single Dose: 1 mg/kg AOC 1001 | Part B Multiple Dose: 2 mg/kg AOC 1001 | Part B Multiple Dose: 4 mg/kg AOC 1001 |
|---|---|---|---|
| Urine Pharmacokinetic (PK) Parameters | 3.724 ± 0.747 | 4.216 ± 2.084 | 4.308 ± 2.087 |
percent change from baseline in DMPK mRNA level
| % change | Part A Single Dose: 1 mg/kg AOC 1001 | Part B Multiple Dose: 2 mg/kg AOC 1001 | Part B Multiple Dose: 4mg/kg AOC 1001 | Pooled Placebo |
|---|---|---|---|---|
| Change From Baseline in DMPK mRNA Knockdown | -46.36 ± 8.85 | -44.39 ± 3.80 | -36.81 ± 6.34 | 1.46 ± 11.17 |
Change from baseline in 4 gene panel mean scaled percent spliced in value. The 4 gene panel includes the following genes: CLCN1, CACNA1S, ATP2A1, and BIN1
| percent | Part A Single Dose: 1 mg/kg AOC 1001 | Part B Multiple Dose: 2 mg/kg AOC 1001 | Part B Multiple Dose: 4mg/kg AOC 1001 | Pooled Placebo |
|---|---|---|---|---|
| Absolute Change From Baseline in 4 Gene Spliceopathy | -3.13 ± 8.39 | -16.72 ± 7.65 | -15.81 ± 10.30 | -6.97 ± 9.68 |
AOC 1001 concentration measures in plasma, urine, and muscle tissue. Assessments below lower limit of quantification are set to zero.
| nM | Part A Single Dose: 1 mg/kg AOC 1001 | Part B Multiple Dose: 2 mg/kg AOC 1001 | Part B Multiple Dose: 4 mg/kg AOC 1001 |
|---|---|---|---|
| Plasma siDMPK.19: first dose, end of Infusion | 1749 ± 109.26 | 3670.18 ± 236.29 | 7234.72 ± 415.56 |
| Plasma siDMPK.19: first dose, 1 hour post-infusion | 1623.12 ± 86.83 | 3632.49 ± 246.59 | 7281.03 ± 365.77 |
| Plasma siDMPK.19: first dose, 2 hours post infusion | 1596.32 ± 89.48 | 3410.50 ± 276.98 | 7050.49 ± 379.32 |
| Plasma siDMPK.19: first dose, 6 hours post infusion | 1379.38 ± 102.25 | 3018.71 ± 243.95 | 6419.49 ± 399.580 |
| Plasma siDMPK.19: first dose, 24 hours post infusion | 841.88 ± 56.13 | 2052.98 ± 148.097 | 4666.17 ± 301.02 |
| Plasma siDMPK.19: first dose, 8 days post infusion | 38.18 ± 10.16 | 152.66 ± 27.95 | 465.92 ± 41.74 |
| Plasma siDMPK.19: first dose, 15 days post infusion | 0.46 ± 0.18 | 9.46 ± 8.79 | 44.01 ± 17.99 |
| Plasma siDMPK.19: first dose, 29 days post infusion | 0.00 ± 0.00 | 0.11 ± 0.06 | 0.69 ± 0.14 |
| Plasma siDMPK.19: first dose, 43 days post infusion | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.05 ± 0.03 |
| Urine siDMPK.19: first dose, 0-6 hours post infusion | 55.38 ± 26.22 | 256.64 ± 73.72 | 196.331 ± 38.415 |
| Urine siDMPK.19: first dose, 6-12 hours | 227.91 ± 53.89 | 419.66 ± 82.97 | 653.42 ± 100.98 |
| Urine siDMPK.19: first dose, 12-24 hours | 161.79 ± 26.95 | 387.46 ± 113.47 | 648.11 ± 109.66 |
| Muscle siDMPK.19: first dose, Day 43 (1 mg/kg) or 92 (2 mg/kg and 4 mg/kg) | 0.085 ± 0.054 | 0.424 ± 0.159 | 1.414 ± 0.417 |
Collected over Treatment-emergent adverse events (TEAES) were collected from the start of the first dose administration through study completion (approximately 6 months for participants who completed the study).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A Single Dose: 1 mg/kg AOC 1001 | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Part A Single Dose: Placebo | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Part B Multiple Dose: 2 mg/kg ACO 1001 | 0/9 (0%) | 1/9 (11.1%) | 9/9 (100%) |
| Part B Multiple Dose: 4 mg/kg AOC 1001 | 0/13 (0%) | 1/13 (7.7%) | 13/13 (100%) |
| Part B Multiple Dose: Pooled Placebo | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Event | Part A Single Dose: 1 mg/kg AOC 1001 | Part A Single Dose: Placebo | Part B Multiple Dose: 2 mg/kg ACO 1001 | Part B Multiple Dose: 4 mg/kg AOC 1001 | Part B Multiple Dose: Pooled Placebo |
|---|---|---|---|---|---|
| Respiratory FailureRespiratory, thoracic and mediastinal disorders | 0/6 | 0/2 | 1/9 | 0/13 | 0/8 |
| Thalmus haemorrhageNervous system disorders | 0/6 | 0/2 | 0/9 | 1/13 | 0/8 |
| Event | Part A Single Dose: 1 mg/kg AOC 1001 | Part A Single Dose: Placebo | Part B Multiple Dose: 2 mg/kg ACO 1001 | Part B Multiple Dose: 4 mg/kg AOC 1001 | Part B Multiple Dose: Pooled Placebo |
|---|---|---|---|---|---|
| fallInjury, poisoning and procedural complications | 1/6 | 1/2 | 1/9 | 0/13 | 4/8 |
| arthropod biteInjury, poisoning and procedural complications | 0/6 | 1/2 | 0/9 | 0/13 | 0/8 |
| concussionInjury, poisoning and procedural complications | 1/6 | 1/2 | 0/9 | 0/13 | 0/8 |
| nasopharyngitisInfections and infestations | 0/6 | 1/2 | 0/9 | 2/13 | 0/8 |
| paraesthesiaNervous system disorders | 0/6 | 1/2 | 1/9 | 1/13 | 0/8 |
| coughRespiratory, thoracic and mediastinal disorders | 0/6 | 1/2 | 0/9 | 0/13 | 0/8 |
| anaemiaBlood and lymphatic system disorders | 0/6 | 0/2 | 1/9 | 6/13 | 0/8 |
| procedural painInjury, poisoning and procedural complications | 0/6 | 0/2 | 4/9 | 4/13 | 0/8 |
| COVID-19Infections and infestations | 2/6 | 0/2 | 3/9 | 2/13 | 1/8 |
| arthralgiaMusculoskeletal and connective tissue disorders | 2/6 | 0/2 | 1/9 | 0/13 | 1/8 |
| Age, Categorical(Participants) | Part A Single Dose: 1 mg/kg AOC 1001 | Part A Single Dose: Placebo | Part B Multiple Dose: 2 mg/kg AOC 1001 | Part B Multiple Dose: 4mg/kg AOC 1001 | Part B Multiple Dose: Pooled Placebo | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 2 | 9 | 13 | 8 | 38 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Part A Single Dose: 1 mg/kg AOC 1001 | Part A Single Dose: Placebo | Part B Multiple Dose: 2 mg/kg AOC 1001 | Part B Multiple Dose: 4mg/kg AOC 1001 | Part B Multiple Dose: Pooled Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 37.0 ± 18 | 40.5 ± 9.2 | 37.6 ± 13.6 | 44.0 ± 12.4 | 48.0 ± 8.5 | 42.0 ± 12.9 |
| Sex: Female, Male(Participants) | Part A Single Dose: 1 mg/kg AOC 1001 | Part A Single Dose: Placebo | Part B Multiple Dose: 2 mg/kg AOC 1001 | Part B Multiple Dose: 4mg/kg AOC 1001 | Part B Multiple Dose: Pooled Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 5 | 1 | 9 | 9 | 4 | 28 |
| Male | 1 | 1 | 0 | 4 | 4 | 10 |
| Race (NIH/OMB)(Participants) | Part A Single Dose: 1 mg/kg AOC 1001 | Part A Single Dose: Placebo | Part B Multiple Dose: 2 mg/kg AOC 1001 | Part B Multiple Dose: 4mg/kg AOC 1001 | Part B Multiple Dose: Pooled Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 1 | 0 | 1 |
| White | 6 | 2 | 9 | 10 | 8 | 35 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 0 | 1 |
| Region of Enrollment(participants) | Part A Single Dose: 1 mg/kg AOC 1001 | Part A Single Dose: Placebo | Part B Multiple Dose: 2 mg/kg AOC 1001 | Part B Multiple Dose: 4mg/kg AOC 1001 | Part B Multiple Dose: Pooled Placebo | Total |
|---|---|---|---|---|---|---|
| United States | 6 | 2 | 9 | 13 | 8 | 38 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2021 to primary completion in Feb 2023, 15 months.
Results were first posted in Sep 2026, 3 years 7 months after primary completion. A results delay was requested in Feb 2024.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AOC 1001